The role also leads the modernization of CDM into a technology-enabled, risk-based function, applying automation, advanced analytics, and responsibly governed AI/ML to improve data quality, shorten cycle times, and reduce site and patient burden, while maintaining compliance with GCP, ICH E6(R3), and evolving health authority expectations for AI in drug development. Ensure oversight and governance of CDM deliverables across the study lifecycle (start-up, conduct, database lock, archival), covering EDC and other clinical data sources including eCOA/ePRO, imaging, central lab, and biomarker data.